| Literature DB >> 23799967 |
Abstract
BACKGROUND: Cells are exposed to multiple stressors that induce significant alterations in signaling pathways and in the cellular state. As obligate parasites, all viruses require host cell material and machinery for replication. Virus infection is a major stressor leading to numerous induced modifications. Previous gene array studies have measured infected cellular transcriptomes. More recently, mass spectrometry-based quantitative and comparative assays have been used to complement such studies by examining virus-induced alterations in the cellular proteome.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23799967 PMCID: PMC3847587 DOI: 10.1186/1743-422X-10-202
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Figure 1Confirmation of HeLa cell infectivity. A, HeLa cells were mock-infected (top), or infected with MRV strain T3D at an MOI of 7 (bottom). Cells were imaged at indicated times post-infection (labeled at top) with a Nikon TE-2000 inverted microscope and photographed with a Canon A700 digital camera. Images were imported into Adobe and slight adjustments made in brightness and contrast, that did not alter image context. Scale bar is 50 μm. B, Kinetics of virus production (▼) and cell viability after HeLa cells were infected (○) or mock-infected (●) with T3D. Error bars represent standard error of the mean from 2 or more replicates.
Number of peptides, proteins, logInfected: Mock (I:M) ratio means and standard deviation, and Z-scores of SILAC-measured HeLa cell proteins after T3D infection
| | ||||
|---|---|---|---|---|
| Total number of peptide pairs1 | 22,591 | 34,393 | 8,011 | 8,974 |
| Total number of proteins2 | 2,067 | 2,787 | 670 | 728 |
| Number of proteins analysed3 | 1,987 | 2,684 | 635 | 686 |
| Mean Log2 I:M ratios | 0.0147 | 0.0126 | 0.0004 | 0.0187 |
| Standard deviation of Log2 I:M ratios | 0.3382 | 0.4211 | 0.4664 | 0.3423 |
| Number of proteins at Z-score cutoff of: ± 1.960σ (95%) | 33, 224 | 50, 20 | 7, 4 | 20, 12 |
| ± 2.576σ (99%) | 24, 11 | 29, 11 | 5, 2 | 14, 8 |
| ± 3.291σ (99.9%) | 14, 7 | 23, 8 | 2, 2 | 8, 4 |
1 Total number of H:L peptide pairs for all proteins identified at confidence level ≥ 99%.
2 Total number of proteins identified at confidence level ≥ 99%.
3 Number of proteins analyzed after those identified by only a single peptide, as well as possible contaminants, removed.
4 First value is number of up-regulated proteins outside the indicated confidence level; second number is number of down-regulated proteins outside the indicated confidence level.
Figure 2Distributions of proteins identified in various experiments. A, Venn diagram of numbers of identified proteins from various analyses. B, Frequency distributions of identified proteins in both cytosolic sample sets, with I:M ratios expressed as Log2 values. Positive values represent up-regulated host proteins in virus-infected cells; negative values represent down-regulated host proteins. C, Frequency distributions of identified proteins in both nuclear sample sets. Note that distributions are not identical, with different numbers of proteins differentially expressed away from the major central peak. Characteristics of all peptide and protein distributions, mean log2 I:M ratios and standard deviations of log2 I:M ratios are shown in Table 1.
Significantly-regulated HeLa cell proteins after T3D infection
| | | | | | | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | ||
| | | | | | | | | | | ||
| | | | | | | | | ||||
| | gi|222136619 | MX1 | myxovirus resistance protein 1 | 9.76 | 0.52 | 8 | 55.9 | 10.925 | 23 | 51.7 | 7.427 |
| | gi|94536771 | CCD56 | coiled-coil domain containing 56 | 5.48 | 1.62 | 5 | 56.6 | 0.223 | 3 | 20.7 | 15.154 |
| | gi|27881482 | DDX58 | DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide RIG-I | 4.76 | 0.83 | 3 | 27.7 | 7.191 | 12 | 23.2 | 5.203 |
| | gi|72534658 | IFIT3 | interferon-induced protein with tetratricopeptide repeats 3 | 4.65 | 0.39 | 4 | 25.3 | 7.260 | 14 | 46.9 | 5.067 |
| | gi|4826774 | ISG15 | ISG15 ubiquitin-like modifier | 4.60 | 0.51 | 14 | 47.3 | 6.164 | 14 | 53.9 | 5.442 |
| | gi|116534937 | IFIT1 | interferon-induced protein with tetratricopeptide repeats 1 isoform 2 | 3.80 | 1.36 | 2 | 40.4 | 11.782 | 8 | 25.1 | 3.308 |
| | gi|156105693 | PR285 | PPAR-alpha interacting complex protein 285 isoform 1 | 3.45 | 1.53 | 2 | 22.0 | 5.564 | 5 | 10.6 | 4.109 |
| | gi|153082755 | IFIT2 | interferon-induced protein with tetratricopeptide repeats 2 | 3.37 | 0.81 | 3 | 33.7 | 1.291 | 11 | 33.1 | 4.978 |
| | gi|6274552 | STAT1 | signal transducer and activator of transcription 1 isoform alpha | 3.23 | 0.39 | 13 | 44.4 | 4.386 | 34 | 50.4 | 4.170 |
| | gi|45007007 | OAS3 | 2'-5'oligoadenylate synthetase 3 | 3.00 | 0.32 | 4 | 19.5 | 4.560 | 9 | 17.3 | 3.761 |
| | gi|208973246 | DHPR | quinoid dihydropteridine reductase | 2.40 | 0.48 | 2 | 27.9 | 0.693 | 4 | 20.5 | 4.171 |
| | gi|38201706 | SAMD9 | sterile alpha motif domain containing 9 | 2.15 | 0.48 | 1 | 18.8 | 2.560 | 10 | 15.4 | 2.648 |
| | gi|4506103 | E2AK2 | eukaryotic translation initiation factor 2-alpha kinase 2 | 1.97 | 0.72 | 3 | 45.7 | 2.503 | 10 | 16.2 | 2.374 |
| | gi|24307901 | IFI35 | interferon-induced protein 35 | 1.92 | 0.44 | 3 | 29.2 | 2.119 | 5 | 18.4 | 2.508 |
| | gi|166706903 | GBP1 | guanylate binding protein 1, interferon-inducible, 67 kDa | 1.85 | 0.88 | 5 | 25.7 | 1.682 | 11 | 27.2 | 2.393 |
| | gi|5031863 | LG3BP | galectin 3 binding protein | 1.81 | 0.86 | 6 | 19.5 | 1.731 | 12 | 29.2 | 2.303 |
| | gi|22035653 | APOL2 | apolipoprotein L2 | 1.80 | 0.53 | 4 | 30.3 | 1.501 | 6 | 32.6 | 2.507 |
| | gi|27477136 | ZCCHV | zinc finger antiviral protein isoform 1 | 1.80 | 0.69 | 2 | 26.2 | 2.245 | 16 | 25.5 | 2.007 |
| | gi|20270303 | MIRO2 | ras homolog gene family, member T2 | 1.79 | 0.92 | 2 | 15.7 | 9.955 | 6 | 15.7 | −0.055 |
| | gi|4757876 | BST2 | bone marrow stromal cell antigen 2 | 1.68 | 0.38 | 5 | 19.4 | 1.610 | 5 | 18.3 | 2.201 |
| | gi|188528628 | PNPT1 | polyribonucleotide nucleotidyltransferase 1 | 1.63 | 0.20 | 13 | 47.6 | 2.221 | 24 | 36.8 | 1.575 |
| | | | | | | | | | |||
| | gi|156415992 | ATP8* | transcription factor B1, mitochondrial | 84.09 | 0.71 | | | | 2 | 9.2 | 15.154 |
| | gi|4557321 | APOA1 | apolipoprotein A-I preproprotein | 7.99 | 0.97 | | | | 2 | 23.2 | 7.089 |
| | gi|11342664 | MX2 | myxovirus resistance protein 2 | 7.72 | 0.57 | | | | 6 | 11.3 | 6.972 |
| | gi|4502511 | CO9 | complement component 9 precursor | 7.26 | 4.88 | | | | 2 | 5.0 | 6.760 |
| | gi|166706909 | IF44L | interferon-induced protein 44-like | 6.18 | 3.89 | | | | 3 | 15.9 | 6.211 |
| | gi|74229015 | OAS1 | 2',5'-oligoadenylate synthetase 1 isoform 3 | 5.85 | 0.86 | | | | 3 | 11.6 | 6.024 |
| | gi|19923717 | DTX3L | deltex 3-like | 3.68 | 3.31 | | | | 4 | 9.7 | 4.438 |
| | gi|74229019 | OAS2 | 2'-5'-oligoadenylate synthetase 2 isoform 1 | 3.50 | 2.14 | | | | 2 | 4.9 | 4.263 |
| | gi|41350201 | EPN1 | epsin 1 isoform c | 3.20 | 2.53 | | | | 2 | 5.5 | 3.953 |
| | gi|5174751 | YAP1 | Yes-associated protein 1, 65 kD | 3.12 | 1.32 | | | | 3 | 7.9 | 3.867 |
| | gi|222831595 | DDX60 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 | 2.92 | 1.56 | | | | 5 | 7.6 | 3.636 |
| | gi|15208660 | RO52 | tripartite motif protein 21 | 2.69 | 0.63 | | | | 8 | 22.7 | 3.364 |
| | gi|110825982 | HERC5 | hect domain and RLD 5 | 2.50 | 0.86 | | | | 2 | 4.7 | 3.104 |
| | gi|4557499 | CTBP2 | C-terminal binding protein 2 isoform 1 | 2.49 | 1.36 | | | | 7 | 25.8 | 3.093 |
| | gi|4506191 | PSMB10 | proteasome beta 10 subunit proprotein | 2.21 | 0.71 | | | | 2 | 7.3 | 2.688 |
| | gi|73747915 | TAP2 | transporter 2, ATP-binding cassette, sub-family B isoform 1 | 2.16 | 0.70 | | | | 3 | 10.8 | 2.615 |
| | gi|38016914 | SAMH1 | SAM domain- and HD domain-containing protein 1 | 2.16 | 0.48 | | | | 6 | 21.7 | 2.610 |
| | gi|126012562 | LRP1 | low density lipoprotein-related protein 1 | 2.11 | 0.60 | | | | 3 | 2.9 | 2.529 |
| | gi|4503445 | TYPH | endothelial cell growth factor 1 (platelet-derived) precursor | 2.10 | 0.85 | | | | 2 | 18.1 | 2.504 |
| | gi|6912630 | IFIT5 | interferon-induced protein with tetratricopeptide repeats 5 | 2.05 | 0.63 | | | | 3 | 13.9 | 2.435 |
| | gi|112789562 | IF16 | interferon, gamma-inducible protein 16 | 1.95 | 0.64 | | | | 6 | 21.8 | 2.263 |
| | gi|45580709 | UN93B | unc-93 homolog B1 | 1.93 | 0.77 | | | | 2 | 4.2 | 2.231 |
| | gi|9665248 | TAP1 | transporter 1, ATP-binding cassette, sub-family B | 1.88 | 0.78 | | | | 2 | 11.8 | 2.135 |
| | gi|52630342 | HLA-C | major histocompatibility complex, class I, C precursor | 1.80 | 0.34 | | | | 20 | 45.4 | 1.982 |
| | | | | | | | | | | ||
| | | | | | | | | ||||
| | gi|134288865 | S4A7 | solute carrier family 4, sodium bicarbonate cotransporter, member 7 | 0.064 | 0.21 | 2 | 21.7 | −3.832 | 2 | 3.8 | −15.807 |
| | gi|29294627 | PPFIBP1 | PTPRF interacting protein binding protein 1 isoform 1 | 0.30 | 0.21 | 3 | 26.5 | −10.860 | 3 | 11.0 | 0.328 |
| | gi|4506431 | RASA1 | RAS p21 protein activator 1 isoform 1 | 0.36 | 0.06 | 1 | 16.5 | −1.418 | 2 | 1.8 | −4.688 |
| | gi|5453704 | PRAF3 | ADP-ribosylation-like factor 6 interacting protein 5 | 0.56 | 0.18 | 4 | 40.4 | −3.941 | 2 | 29.8 | 0.235 |
| | gi|21956645 | MTPN | myotrophin | 0.56 | 0.08 | 9 | 49.1 | −4.823 | 8 | 39.0 | 0.091 |
| | | | | | | | | | |||
| | gi|167466177 | CDC27 | cell division cycle protein 27 isoform 1 | 0.010 | 0.36 | | | | 2 | 4.0 | −15.807 |
| | gi|8922549 | ASF1B | anti-silencing function 1B | 0.33 | 0.000 | | | | 2 | 23.8 | −3.834 |
| | gi|33598948 | PLCG1 | phospholipase C gamma 1 isoform a | 0.33 | 0.34 | | | | 2 | 6.9 | −3.803 |
| | gi|46049063 | XPO6 | exportin 6 | 0.34 | 0.05 | | | | 2 | 5.2 | −3.706 |
| | gi|116734706 | I2BP2 | interferon regulatory factor 2 binding protein 2 isoform B | 0.36 | 0.38 | | | | 3 | 13.7 | −3.517 |
| | gi|116686114 | FERM1 | kindlin-1 | 0.38 | 0.004 | | | | 3 | 12.3 | −3.348 |
| | gi|5453543 | AK1C1 | aldo-keto reductase family 1, member C1 | 0.39 | 0.05 | 14 | 72.8 | −4.099 | | | |
| | gi|63025188 | HERC4 | hect domain and RLD 4 isoform a | 0.41 | 0.000 | | | | 2 | 2.5 | −3.077 |
| | gi|14589951 | RPAB1 | DNA directed RNA polymerase II polypeptide E | 0.46 | 0.14 | | | | 6 | 21.4 | −2.683 |
| | gi|51317370 | NDUA6 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kDa | 0.47 | 0.000 | | | | 2 | 14.9 | −2.637 |
| | gi|10190746 | RDH14 | retinol dehydrogenase 14 (all-trans and 9-cis) | 0.51 | 0.38 | | | | 2 | 8.6 | −2.306 |
| | gi|13236559 | MMTA2 | hypothetical protein LOC79169 | 0.54 | 0.01 | | | | 2 | 35.0 | −2.138 |
| | gi|115430235 | UHRF1 | ubiquitin-like with PHD and ring finger domains 1 isoform 1 | 0.55 | 0.10 | | | | 2 | 11.1 | −2.105 |
| | gi|71773010 | AP1G1 | adaptor-related protein complex 1, gamma 1 subunit isoform a | 0.55 | 0.25 | 4 | 22.3 | −2.570 | | | |
| | | | | | | | | | | ||
| | | | | | | | | | | ||
| | | | | | | | | ||||
| | gi|4826774 | ISG15 | ISG15 ubiquitin-like modifier | 4.05 | 0.40 | 5 | 42.4 | 4.065 | 4 | 23.0 | 6.275 |
| | gi|19923236 | SP100 | nuclear antigen Sp100 isoform 2 | 2.96 | 0.93 | 4 | 18.1 | 2.812 | 8 | 26.2 | 4.880 |
| | gi|112789562 | IF16 | interferon, gamma-inducible protein 16 | 2.92 | 0.40 | 2 | 11.8 | 2.384 | 6 | 19.3 | 4.879 |
| | gi|67089149 | PML | promyelocytic leukemia protein isoform 1 | 2.34 | 0.60 | 2 | 8.4 | 2.758 | 9 | 21.7 | 3.496 |
| | gi|4757876 | BST2 | bone marrow stromal cell antigen 2 | 2.03 | 0.56 | 3 | 18.3 | 2.512 | 2 | 13.9 | 2.290 |
| | | | | | | | | | |||
| | gi|4503253 | DAD1 | defender against cell death 1 | 5.22 | 0.62 | 3 | 17.7 | 5.110 | | | |
| | gi|188219599 | NMI | N-myc and STAT interactor | 4.33 | 1.17 | | | | 2 | 16.9 | 6.125 |
| | gi|24307901 | IFI35 | interferon-induced protein 35 | 3.60 | 0.93 | | | | 3 | 15.6 | 5.347 |
| | gi|4758024 | COIL | coilin | 2.46 | 0.83 | 2 | 12.8 | 2.788 | | | |
| | gi|5453690 | DNJB1 | DnaJ (Hsp40) homolog, subfamily B, member 1 | 2.32 | 0.000 | | | | 2 | 11.8 | 3.499 |
| | gi|58530840 | DESP | desmoplakin isoform I | 2.09 | 0.91 | | | | 3 | 9.3 | 3.054 |
| | gi|156104878 | GLSK | glutaminase | 2.03 | 0.75 | | | | 3 | 4.8 | 2.931 |
| | gi|27477136 | ZCCHV | zinc finger antiviral protein isoform 1 | 1.95 | 0.74 | | | | 2 | 2.2 | 2.754 |
| | gi|4507951 | 1433F | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide | 1.89 | 1.06 | | | | 2 | 22.8 | 2.633 |
| | gi|5901998 | LSM6 | Sm protein F | 1.85 | 0.60 | | | | 3 | 56.3 | 2.538 |
| | gi|4506003 | PP1A | protein phosphatase 1, catalytic subunit, alpha isoform 1 | 1.70 | 0.95 | | | | 4 | 13.9 | 2.184 |
| | | | | | | | | | | ||
| | | | | | | | | ||||
| | gi|55953087 | NOG1 | G protein-binding protein CRFG | 0.10 | 0.21 | 2 | 4.4 | −13.385 | 2 | 6.3 | −1.353 |
| | gi|4503453 | EDF1 | endothelial differentiation-related factor 1 isoform alpha | 0.63 | 0.17 | 4 | 28.4 | −0.672 | 4 | 41.2 | −2.991 |
| | gi|4507555 | LAP2A | thymopoietin isoform alpha | 0.64 | 0.03 | 10 | 15.3 | −2.464 | 10 | 12.5 | −0.479 |
| | | | | | | | | | |||
| | gi|88853069 | VTNC | vitronectin precursor | 0.013 | 0.04 | 2 | 4.8 | −13.385 | | | |
| | gi|25777615 | PSD7 | proteasome 26S non-ATPase subunit 7 | 0.39 | 0.30 | | | | 3 | 12.3 | −4.046 |
| | gi|4757732 | AIFM1 | programmed cell death 8 isoform 1 | 0.40 | 0.18 | | | | 2 | 18.4 | −3.870 |
| | gi|57863257 | TCPA | T-complex protein 1 isoform a | 0.50 | 0.04 | | | | 2 | 5.2 | −2.951 |
| | gi|4506701 | RS23 | ribosomal protein S23 | 0.54 | 0.19 | | | | 4 | 32.9 | −2.647 |
| gi|151108473 | FIS1 | tetratricopeptide repeat domain 11 | 0.63 | 0.000 | 2 | 7.2 | −1.990 | ||||
*: Obsolete record; removed from NCBI database.
Figure 3Gene ontology analyses of up-regulated and down-regulated proteins. Sets of up- and down-regulated proteins identified in Table 2 were separately imported into the DAVID gene ontology suite of programs at the NIAID, gene identifications converted by that program, and ontological functions determined by GOTERM.
Figure 4Molecular pathways of regulated proteins. Proteins and their levels of regulation were imported into the Ingenuity Pathways Analysis (IPA™) tool and interacting pathways were constructed. A, Ontological classifications of all measured proteins (Total) as well as those significantly up- and down-regulated. B, Merged networks, determined by uploading the regulated proteins only into STRING [54,55] (left), or by uploading all molecules and their degree of regulation into IPA™ (middle). C-F, The top 4 IPA networks, identified at 95% confidence and each of which contained 12 or more “focus” molecules (molecules significantly up- or down-regulated), with pathway names indicated. Solid lines: direct known interactions; dashed lines: suspected or indirect interactions. Significantly regulated proteins identified in either the cytosolic or nuclear fractions were overlaid onto each network; red: significantly up-regulated proteins; pink: moderately up-regulated proteins; grey: proteins identified but not significantly regulated; light green: moderately down-regulated proteins; dark green: significantly down-regulated proteins; white: proteins known to be in network, but not identified in our study.
Figure 5Significantly affected canonical pathway “Interferon signaling”, as determined by IPAanalysis. Red indicates highly up-regulated proteins, light green indicates down-regulated, grey represents not significantly affected, and white represents molecules known to be part of the pathway but not identified by SILAC.
Figure 6Western blot validation of host protein regulation. A, HeLa cells were mock-infected or infected for 24 h, or B, for indicated periods of time, harvested and lysed with 0.5% NP-40 detergent. The cytosolic and nuclear fractions were separately purified, dissolved in SDS electrophoresis sample buffer, and proteins resolved in 10% (A), or in 4-16% gradient (B) SDS-PAGE, transferred to PVDF, and probed with indicated antibodies. Antibody binding was detected with HRP-conjugated secondary antibodies and ECL, and visualized with an Alpha Innotech FluorChemQ MultiImage III instrument. Molecular weight standards are indicated at left and SILAC-measured ratios are indicated on right in A. *: not detected in indicated fraction; †: based on single peptide only.